Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. Its veterinary vaccines include monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. The company also develops vaccines for household animals. In addition, it exports its products …
Full ZYBT analysis →
Competitive advantage assessment
Key risks
Commodity Pressure / Weak DifferentiationGross margin at 13.8th percentile with high volatility suggests weak pricing power or commoditized products.
Where ZYBT ranks in Drug Manufacturers - Specialty & Generic
Zhengye Biotechnology Holding L ranks #62 of 91
scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 68%.
The widest moat in the group is Zoetis Inc. (ZTS)
at 85/100.
Moat scores for companies ranked near ZYBT in Drug Manufacturers - Specialty & Generic
Pricing power is the ability to raise prices without losing volume.
Cost Advantage
Score 28
· 15% of the moat score
A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.
Customer Stickiness
Score 56
· 15% of the moat score
Stickiness is what makes revenue repeat without being re-won every year.
Capital Efficiency
Score 34
· 18% of the moat score
Capital efficiency asks what the company earns on the money tied up in the business.
Resilience
Score 38
· 17% of the moat score
Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.
Scale & Market Position
Score 15
· 15% of the moat score
Scale matters only when it converts into economics.
What is Zhengye Biotechnology Holding L's moat score?
Zhengye Biotechnology Holding L (ZYBT) scores 32 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #62 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 68%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Customer Stickiness (56/100) and its weakest is Scale & Market Position (15/100).
How does Zhengye Biotechnology Holding L compare with other Drug Manufacturers - Specialty & Generic companies?
Zhengye Biotechnology Holding L ranks #62 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are Cardiol Therapeutics Inc. (CRDL) at 33 just above it and Assertio Holdings, Inc. (ASRT) at 32 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.
Why is Zhengye Biotechnology Holding L scored with the Corporate Default template?
Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.
Which competitive defenses are measured for Zhengye Biotechnology Holding L?
The Corporate Default template measures 6 defenses, and ZYBT scores: Pricing Power (24), Cost Advantage (28), Customer Stickiness (56), Capital Efficiency (34), Resilience (38), Scale & Market Position (15). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.